GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Vir Biotechnology, Inc. (VIR)
Company Research
Source: GlobeNewswire
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaksPromising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five monthsGSK to make equity investment of $250 million in Vir LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in f
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024Business Wire
- With 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing [Yahoo! Finance]Yahoo! Finance
- What Makes Vir Biotechnology (VIR) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 2/22/24 - Beat
VIR
Analyst Actions
- 2/23/24 - JP Morgan
VIR
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- VIR's page on the SEC website